These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237 [TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer. Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393 [TBL] [Abstract][Full Text] [Related]
6. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles. Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424 [TBL] [Abstract][Full Text] [Related]
8. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery. Leach JC; Wang A; Ye K; Jin S Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893 [TBL] [Abstract][Full Text] [Related]
9. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators. Shaw BR; Moussa L; Sharaf M; Cheek M; Dobrikov M Nucleic Acids Symp Ser (Oxf); 2008; (52):655-6. PubMed ID: 18776550 [TBL] [Abstract][Full Text] [Related]
11. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100 [TBL] [Abstract][Full Text] [Related]
12. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice. Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer. Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828 [No Abstract] [Full Text] [Related]
14. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627 [TBL] [Abstract][Full Text] [Related]
15. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer. Liu HY; Yu X; Liu H; Wu D; She JX Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457 [TBL] [Abstract][Full Text] [Related]
16. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566 [TBL] [Abstract][Full Text] [Related]
17. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916 [TBL] [Abstract][Full Text] [Related]
18. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500 [TBL] [Abstract][Full Text] [Related]
19. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo. Liu R; Sun J; Zhang Z; Xu Y Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256 [TBL] [Abstract][Full Text] [Related]
20. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Gu F; Langer R; Farokhzad OC Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]